Sendai Virus Vector for Sustained Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors, particularly those using Sendai virus, face challenges in achieving sustained gene expression over a long period while maintaining safety, as they often exhibit cytotoxicity and limited persistence, and are transmissible, posing safety concerns.
Innovation Solution
Development of a Sendai virus vector derived from the temperature-sensitive mutant strain C1.151, which includes specific mutations in the M, F, and L proteins to enhance persistent infection and reduce cytotoxicity, and modification to render the vector non-transmissible by defecting genes such as M, F, and HN, ensuring safety and prolonged gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Sendai virus vectors based on Z strain are used to achieve gene expression, then gene expression activity is high, but cytotoxicity occurs and gene expression lasts only a limited period
Solution Approach 1:
The patent applies parameter changes by modifying the temperature sensitivity characteristics of the Sendai virus vector. The vector is engineered to be temperature-sensitive, allowing it to replicate and express genes actively at lower temperatures (34°C) while being restricted at body temperature (37°C). This temperature-dependent parameter change enables both high gene expression activity during treatment and automatic limitation of expression duration, resolving the contradiction between productivity and duration.
2Duration of action of moving object
If Sendai virus vectors are used to achieve sustained gene expression, then gene expression lasts longer, but the vectors remain transmissible posing safety concerns
Solution Approach 1:
The patent uses parameter changes by implementing temperature sensitivity as a control mechanism. The Sendai virus vector is designed to be active only at temperatures below body temperature (34°C vs 37°C), which automatically limits its transmissibility in vivo while allowing sustained gene expression in controlled environments. This parameter-based control resolves the safety concern while maintaining expression duration.
Solution Approach 2:
The patent converts the potential harm of transmissibility into a benefit by using temperature sensitivity as a dual-purpose mechanism. The same temperature sensitivity that limits viral replication in the body also ensures sustained expression in controlled settings, transforming a safety risk into a controllable feature that benefits both safety and expression duration.
3Object-affected harmful factors
If temperature-sensitive mutant strain C1.151 is used to reduce cytotoxicity, then cytotoxicity is reduced, but gene expression activity and persistence are limited
Solution Approach 1:
The patent applies parameter changes by optimizing the temperature sensitivity parameters of strain C1.151. By carefully tuning the temperature threshold and replication kinetics, the vector achieves low cytotoxicity at physiological temperatures while maintaining high gene expression activity at permissive temperatures. This parameter optimization resolves the contradiction between reducing harm and maintaining productivity.
Data Source
AI summary
A persistently infective virus vector is produced by using a gene so modified as to encode an amino acid sequence including a valine substituted for an amino acid residue at position-1618 in the amino acid sequence for an L protein of a persistently non-infective Sendai virus. A non-transmissible, persistently infective virus vector is also produced by defecting or deleting at least one of M gene, F gene, and HN gene. These virus vectors have no cytotoxicity, can achieve the sustained gene expression over a long period of time, is safe, and is therefore useful.